Literature DB >> 11391090

The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease.

H Feldman1, A Sauter, A Donald, I Gélinas, S Gauthier, K Torfs, W Parys, A Mehnert.   

Abstract

The Disability Assessment for Dementia (DAD) scale was developed and validated as a measure of functional ability in dementia. DAD results have been reported in Alzheimer disease (AD) randomized, controlled treatment trials of up to 6 months, but results beyond 6 months have yet to be described. SAB INT 12 was a randomized, double-blind, placebo-controlled, parallel-group study in mild to moderate AD that included DAD assessments at baseline, month 6, and month 12. One hundred forty-four patients with AD in the placebo arm of SAB INT 12 were followed up for 12 months. DAD scores were obtained at baseline (mean DAD = 70.1, SD = 22.2), 6 months (mean DAD = 63.7, SD = 25.2), and 12 months (mean DAD = 59.3, SD = 28.9). The rate of decline was consistent across the domains of basic activities of daily living (ADLs) and instrumental ADLs, as well as the scoring of initiation, planning, and organization. The decline in DAD total scores in mild to moderate AD averages about one point per month, which equates to the loss of one item on the DAD scale every 2 months.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391090     DOI: 10.1097/00002093-200104000-00008

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  27 in total

Review 1.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

2.  Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.

Authors:  Xu Steven Xu; Mahesh Samtani; Min Yuan; Partha Nandy
Journal:  AAPS J       Date:  2014-08-28       Impact factor: 4.009

Review 3.  Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Authors:  Jamie Eberling; Lona Vincent; Jennifer G Goldman; Daniel Weintraub; Jaime Kulisevsky; Connie Marras; Glenn Stebbins; Karl Kieburtz
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

4.  Aerobic Exercise Sustains Performance of Instrumental Activities of Daily Living in Early-Stage Alzheimer Disease.

Authors:  Eric D Vidoni; Jaime Perales; Mohammed Alshehri; Abdul-Mannaan Giles; Catherine F Siengsukon; Jeffrey M Burns
Journal:  J Geriatr Phys Ther       Date:  2019 Jul/Sep       Impact factor: 3.381

5.  Methods and design of the baseline survey of the neurological disorders in Salamanca (NEDISA) cohort: a population-based study in Central-Western Spain.

Authors:  Jesús Cacho; Julián Benito-León; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-01-19       Impact factor: 3.282

Review 6.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  A community-based approach to trials of aerobic exercise in aging and Alzheimer's disease.

Authors:  Eric D Vidoni; Angela Van Sciver; David K Johnson; Jinghua He; Robyn Honea; Brian Haines; Jami Goodwin; M Pat Laubinger; Heather S Anderson; Patricia M Kluding; Joseph E Donnelly; Sandra A Billinger; Jeffrey M Burns
Journal:  Contemp Clin Trials       Date:  2012-08-07       Impact factor: 2.226

Review 8.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.

Authors:  Gary Small; Timo Erkinjuntti; Alexander Kurz; Sean Lilienfeld
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

Authors:  Gordon Wilcock; Ian Howe; Hilary Coles; Sean Lilienfeld; Luc Truyen; Young Zhu; Roger Bullock; Paul Kershaw
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.